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In March of 2008, the Bill & Melinda
Gates Foundation made the impressive
announcement that it will accept proposals
for a new Grand Challenges Explorations
program [1]. Grand Challenges Explora-
tions will provide $100 million for global
health scientists to identify new ways to
protect against infectious diseases (includ-
ing neglected tropical diseases [NTDs]), to
create new drugs or delivery systems, to
prevent or cure HIV/AIDS, and to
explore the basis of latency in tuberculosis
[1]. In so doing, the Gates Foundation will
build on its long-standing multibillion
dollar commitments to develop and test
new drugs, diagnostics, and vaccines for
NTDs, as well as the better known ‘‘big
three’’ diseases, HIV/AIDS, tuberculosis,
and malaria, and to fund critically needed
operational research in support of large-
scale control programs for these conditions
[1]. The Gates Foundation is not alone—
the United Kingdom’s Wellcome Trust
has a £15 billion investment portfolio of
which a significant amount is devoted to
global infectious diseases [2], while the
United States National Institutes of Health
(NIH) also devotes a significant amount of
funding towards global health [3]. There-
fore, in the coming decade we can expect
that these initiatives will contribute signif-
icantly towards reducing the so-called 10/
90 gap, a term coined by the Global Forum
for Health Research to refer to the finding
that only 10% or less of the global
expenditure on medical research and
development is directed towards neglected
health problems that disproportionately
affect the poorest people in developing
regions of sub-Saharan Africa, Asia, and
tropical regions of the Americas.
While these new funded initiatives
portend great promise for addressing the
global 10/90 gap, I am also concerned
that there is an important piece missing
from these efforts that could undermine
their success. I believe that at several levels
we are failing to train the next generation
of global public health scientists who either
have the expertise to build these new
technologies or who will understand how
to apply these new technologies to public
health practice [4–7]. The term appropriate
technology has been used to describe inno-
vations, which are ‘‘developed, produced,
delivered and monitored within a com-
prehensive framework that takes into
account the systems, the individuals, and
the community.’’ [7]. In a previous paper,
my co-authors and I cited as examples of
appropriate technology the storied suc-
cesses of vaccines for polio and measles,
and how because of their appropriate use
these diseases were eradicated from the
Western Hemisphere; in the case of
smallpox vaccine, we have achieved global
eradication [7]. In contrast, the re-emer-
gence of malaria in India and elsewhere as
a consequence of chloroquine drug resis-
tance by the malaria parasite and resis-
tance to DDT by the mosquito vector are
cited as examples of inappropriate use of
technology during the 1960s [7,8]. My
concern is that unless we train a new
generation of global health scientists to use
appropriately the new Gates Foundation–
Wellcome Trust–NIH–Howard Hughes
Medical Institute–funded technologies,
we risk seeing these impressive investments
fail to materialize into innovations that
actually make a difference in the lives of
poor people in developing countries.
So exactly where and how does a person
obtain training in a new type of global
public health practice that embraces
Affymetrix chips as a diagnostic tool for
human African trypanosomiasis or river
blindness; tests of a new drug for the
treatment or chronic Chagas disease;
planning for community-based drug dis-
tributors in order to add mebendazole and
praziquantel to ivermectin for NTD con-
trol together with long-lasting insecticide-
treated nets for co-endemic malaria; or the
development, technology transfer, and
clinical testing new recombinant vaccines
for malaria, tuberculosis, or hookworm
infection? Similarly, where and how does
an individual become trained to simulta-
neously learn how to conduct high
throughput screening for new antimalarial
drugs, or prepare batch production re-
cords for the fermentation of a new
recombinant hookworm antigen? In pre-
vious papers, I have suggested that if we
had to answer the question today then we
could not depend on most of the approx-
imately 40 accredited public health schools
in the United States [4–7]. Such state-
ments were based partly on my personal
experiences as a lecturer at two excellent
public health schools (and my role as a
visitor to several other schools) during
which I was astonished to find that a
majority of my students who were well into
their public health training did not have a
knowledge base that included the etiologic
agent and mosquito vector of severe
malaria, the differences between African
and American trypanosomiasis, or even
the differences between a drug or a
vaccine, much less the technology that is
required to build such control tools.
For me, it did not take long to discover
why American studentswere soill-equipped
to take on substantive global health prob-
lems that require in-depth technical knowl-
Citation: Hotez PJ (2008) Training the Next Generation of Global Health Scientists: A School of Appropriate
Technology for Global Health. PLoS Negl Trop Dis 2(8): e279. doi:10.1371/journal.pntd.0000279
Published August 27, 2008
Copyright:  2008 Peter J. Hotez. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: The author received no specific funding for this article.
Competing Interests: PJH is President of the Sabin Vaccine Institute and Director of the Human Hookworm
Vaccine Initiative, a product development partnership supported by the Bill & Melinda Gates Foundation. He is
an inventor on US Patent 7,303,752 B2 (issued December 4, 2007) entitled ‘‘Hookworm vaccine.’’
* E-mail: mtmpjh@gwumc.edu or photez@gwu.edu
Peter J. Hotez is Editor-in-Chief of PLoS Neglected Tropical Diseases. He is the Walter G. Ross Professor and Chair
of his department, and President of the Sabin Vaccine Institute.
www.plosntds.org 1 August 2008 | Volume 2 | Issue 8 | e279edge. In 2003, I reviewed the departmental
structure of the first generation of US public
health schools and compared it to some of
the newer public health schools, whichwere
established within the last 30 years [5].
Whereas the former under the influence of
the great William Henry Welch included a
heavy component of organism biology,
pathology, and the state-of-the-art technol-
ogies of their day [4], many of the latter
emphasize health promotion, health com-
munication, health policy, and exercise
sciences [5]. Although there is certainly
nothing wrong with these important sub-
jects, I feel it means that the pendulum of
American public health education has
swung heavily towards the social sciences,
often at the expense of microbiology and
infectious diseases [4–7]. In response, at
The George Washington University and
Sabin Vaccine Institute, I helped to create a
new master’s degree curriculum run jointly
between our medical school’s basic science
Department of Microbiology, Immunology,
andTropicalMedicineandtheDepartment
of Epidemiology and Biostatistics in our
public health school. Even this initiative,
however, falls short of what is truly needed
to provide essential competencies in appro-
priate technology.
Since I first wrote those papers 5 years
ago, which called for more technology-
driven curricula, the situation has im-
proved slightly. Competencies in the
biologic basis of public health are now a
core component of graduate training for
the master’s of public health degree [9],
and as shown in Tables 1 and 2, there are
currently 16 American public health
schools with significant commitments to
microbiology, infectious diseases, or bio-
medical sciences. Unfortunately, 11 of
those schools represent the first generation
of public health schools founded before
1970, while only five of the 25 American
pubic health schools founded after 1970
host departments with capacity to begin
addressing appropriate technology instruc-
tion. I feel that the two founding tropical
medicine schools in the United Kingdom,
the Liverpool School of Tropical Medicine
and the London School of Hygiene and
Tropical Medicine, come the closest to
seriously addressing appropriate technolo-
gy in their curricula [6], but even then
they fall short in the areas of new tools
development and testing. Certainly some
of the new interdisciplinary global health
training initiatives funded by the Fogarty
International Center of the NIH, such as
the Frameworks Programs for Global
Health, will address some of these issues
[10]. In the meantime, I am watching with
great hope and expectation the founding
of the new French School for Advanced
Studies in Public Health [11].
At the turn of the 20th century William
Henry Welch, who founded the original
Johns Hopkins School of Public Health,
teamed up with Wickliffe Rose, the
architect of the Rockefeller International
Health Board, in order to establish a plan
for global public health education (the
Rose–Welch Plan) that in some ways
resembled the Flexner Report for medical
education [4]. A new 21st century plan
may be needed to address exactly how we
might train a new generation of global
public health scientists who will leverage
the discoveries and technologies funded by
Gates, Wellcome, Howard Hughes, and
other foundations, as well as the NIH, the
UK Medical Research Council, and their
equivalent organizations in Brazil, China,
India, and elsewhere.
Today, I feel that most of the innova-
tion in global public health technology is
coming not from schools of public health,
but rather the public development part-
nerships (PDPs) and public–private part-
nerships (PPPs), many of which were
launched with support from the Bill &
Melinda Gates Foundation [12–14]. List-
ed in Table 3 are some of the major PDPs,
which are producing an exciting new
generation of products and developing
control methods for the health of devel-
oping countries, and then introducing
these innovations through a program of
global access. As exciting as these new
Table 1. US Accredited Public Health Schools Founded before 1970 with Academic
Departments Devoted to Infectious and Tropical Diseases.
Schools (Alphabetical Order) Year Founded Academic Department or Program
Harvard School of Public Health 1922 Immunology and Infection
Johns Hopkins Bloomberg School of Public
Health
1916 Molecular Microbiology and
Immunology
Tulane University School of Public Health and
Tropical Medicine
1912 Tropical Medicine
University of California at Berkeley School of
Public Health
1943 Infectious Diseases
University of Michigan School of Public Health 1941 Global and International Health
University of North Carolina at Chapel Hill
School of Public Health
1936 Epidemiology
University of Pittsburgh Graduate School of
Public Health
1948 Infectious Diseases and Microbiology
University of Texas School of Public Health 1969 Biomedical Lab Sciences
University of Washington School of Public
Health and Community Medicine
1970 Pathobiology
Yale School of Public Health 1915 Epidemiology of Microbial Disease
Of the 15 accredited US public health schools, 11 host departments in this area.
doi:10.1371/journal.pntd.0000279.t001
Table 2. US Accredited Public Health Schools Founded after 1970 with Academic
Departments Devoted to Infectious and Tropical Diseases.
Schools (Alphabetical Order) Year Founded Academic Department or Program
Emory University Rollins School of Public
Health
1990 Hubert Department of Global Health
George Washington University Schools of
Public Health and Health Service and
Medicine and Health Sciences
1997 Public Health Microbiology and Emerging
Infectious Diseases Program (jointly with
Department of Microbiology, Immunology,
and Tropical Medicine)
Instituto Nacional de Salud Publica
(Cuernavaca, Mexico)
1987 Infectious Diseases Infectious Vector-Borne
Diseases
University at Albany SUNY School of Public
Health
1985 Department of Biomedical Sciences
University of South Florida 1984 Global Health Department
Of the 25 accredited US public health schools, five schools host departments devoted to this area.
doi:10.1371/journal.pntd.0000279.t002
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no mechanism to transfer the knowledge
gained through them to the next genera-
tion of public health students.
As the head of one such PDP, I have
experienced great frustration with the lack
of appropriate training of newly minted
public health graduates. Among the core
competencies that my PDP and others
require are 1) the ability to recognize the
major infectious pathogens with a micro-
scope; cultivation and in vitro mainte-
nance of organisms; and performance of
diagnostic tests; 2) principles of drug
discovery and high throughput screening;
3) principles of vaccine development
including antigen discovery, fermenta-
tion/purification technology, and princi-
ples of quality control and quality assur-
ances; 4) GXP (current good laboratory
practices [GLP], good manufacturing
practices [GMP], and good clinical prac-
tices [GCP]); 5) principles of promoting
global access, such as technology transfer
to innovative developing countries [15],
product introduction, cost-effectiveness,
and financing; 6) regulatory requirements
for new drugs, diagnostics, and biologics;
7) international patent law; 8) basics of
clinical trial design, mathematical princi-
ples essential to understanding transmis-
sion dynamics of disease, and translational
epidemiology; and 9) the major operation-
al research issues associated with large-
scale infectious diseases control programs
[7]. Most of these topics are covered in
PLoS Neglected Tropical Diseases, although it
should be pointed out that many of these
core competencies would also be useful for
addressing the ever-increasing burden of
chronic non-communicable diseases in
middle- and low-income countries [16].
The MPH degree, while important for
many aspects of public health, is simply not
adequate for providing most of the the skills
we need to staff the PDPs and PPPs for
global health technology innovation. We
need additional programs of instruction in
US schools of public health, and possibly a
new type of school of appropriate technology for
global health. Graduates of such a curriculum
should be highly sought after by the PDPs
and PPPs, as well as the pharmaceutical
industry, NIH, US Centers for Disease
Control and Prevention, and the World
Health Organization and other United
Nations agencies committed to global
health. It may be that even the establish-
mentofa singlemajor school ofappropriate
technology for global health would be
sufficient to begin addressing current needs,
and then elements of suchinstruction would
in time diffuse to more conventional schools
of public health. Equally important, we
need to address training needs in middle-
and low-income countries where the ne-
glected diseases are endemic by identifying
centers of excellence in global health
technologyandexpandingtheopportunities
for young scientists to obtain training in
core competencies relevant to product and
clinical development, GXP, and global
access. In so doing, we could maximize
the growing capacity for innovation in
developing countries [17].
In my opinion, there is unprecedented
interest by young people to solve global
public health problems of importance to
the developing world. We need now to
harness that youthful energy and channel
it appropriately.
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